James D Murphy1, Grace L Ma2,3, Joel M Baumgartner2, Lisa Madlensky4, Adam M Burgoyne5, Chih-Min Tang2, Maria Elena Martinez4, Jason K Sicklick2. 1. Department of Radiation and Applied Sciences, Moores Cancer Center, University of California San Diego, La Jolla, California. 2. Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, California. 3. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania. 4. Department of Family and Preventive Medicine, Moores Cancer Center, University of California San Diego, La Jolla, California. 5. Division of Medical Oncology, Department of Internal Medicine, Moores Cancer Center, University of California San Diego, La Jolla, California.
Abstract
BACKGROUND: Most gastrointestinal stromal tumors (GISTs) are considered nonhereditary or sporadic. However, single-institution studies suggest that GIST patients develop additional malignancies at increased frequencies. It was hypothesized that greater insight could be gained into possible associations between GISTs and other malignancies with a national cancer database inquiry. METHODS: Patients diagnosed with GISTs (2001-2011) in the Surveillance, Epidemiology, and End Results database were included. Standardized prevalence ratios (SPRs) and standardized incidence ratios (SIRs) were used to quantify cancer risks incurred by GIST patients before and after GIST diagnoses, respectively, in comparison with the general US population. RESULTS: There were 6112 GIST patients, and 1047 (17.1%) had additional cancers. There were significant increases in overall cancer rates: 44% (SPR, 1.44) before the GIST diagnosis and 66% (SIR, 1.66) after the GIST diagnosis. Malignancies with significantly increased occurrence both before and after diagnoses included other sarcomas (SPR, 5.24; SIR, 4.02), neuroendocrine-carcinoid tumors (SPR, 3.56; SIR, 4.79), non-Hodgkin lymphoma (SPR, 1.69; SIR, 1.76), and colorectal adenocarcinoma (SPR, 1.51; SIR, 2.16). Esophageal adenocarcinoma (SPR, 12.0), bladder adenocarcinoma (SPR, 7.51), melanoma (SPR, 1.46), and prostate adenocarcinoma (SPR, 1.20) were significantly more common only before the GIST diagnosis. Ovarian carcinoma (SIR, 8.72), small intestine adenocarcinoma (SIR, 5.89), papillary thyroid cancer (SIR, 5.16), renal cell carcinoma (SIR, 4.46), hepatobiliary adenocarcinoma (SIR, 3.10), gastric adenocarcinoma (SIR, 2.70), pancreatic adenocarcinoma (SIR, 2.03), uterine adenocarcinoma (SIR, 1.96), non-small cell lung cancer (SIR, 1.74), and transitional cell carcinoma of the bladder (SIR, 1.65) were significantly more common only after the GIST diagnosis. CONCLUSIONS: This is the first population-based study to characterize the associations and temporal relations between GISTs and other cancers by both site and histological type. These associations may carry important clinical implications for future cancer screening and treatment strategies.
BACKGROUND: Most gastrointestinal stromal tumors (GISTs) are considered nonhereditary or sporadic. However, single-institution studies suggest that GIST patients develop additional malignancies at increased frequencies. It was hypothesized that greater insight could be gained into possible associations between GISTs and other malignancies with a national cancer database inquiry. METHODS:Patients diagnosed with GISTs (2001-2011) in the Surveillance, Epidemiology, and End Results database were included. Standardized prevalence ratios (SPRs) and standardized incidence ratios (SIRs) were used to quantify cancer risks incurred by GIST patients before and after GIST diagnoses, respectively, in comparison with the general US population. RESULTS: There were 6112 GIST patients, and 1047 (17.1%) had additional cancers. There were significant increases in overall cancer rates: 44% (SPR, 1.44) before the GIST diagnosis and 66% (SIR, 1.66) after the GIST diagnosis. Malignancies with significantly increased occurrence both before and after diagnoses included other sarcomas (SPR, 5.24; SIR, 4.02), neuroendocrine-carcinoid tumors (SPR, 3.56; SIR, 4.79), non-Hodgkin lymphoma (SPR, 1.69; SIR, 1.76), and colorectal adenocarcinoma (SPR, 1.51; SIR, 2.16). Esophageal adenocarcinoma (SPR, 12.0), bladder adenocarcinoma (SPR, 7.51), melanoma (SPR, 1.46), and prostate adenocarcinoma (SPR, 1.20) were significantly more common only before the GIST diagnosis. Ovarian carcinoma (SIR, 8.72), small intestine adenocarcinoma (SIR, 5.89), papillary thyroid cancer (SIR, 5.16), renal cell carcinoma (SIR, 4.46), hepatobiliary adenocarcinoma (SIR, 3.10), gastric adenocarcinoma (SIR, 2.70), pancreatic adenocarcinoma (SIR, 2.03), uterine adenocarcinoma (SIR, 1.96), non-small cell lung cancer (SIR, 1.74), and transitional cell carcinoma of the bladder (SIR, 1.65) were significantly more common only after the GIST diagnosis. CONCLUSIONS: This is the first population-based study to characterize the associations and temporal relations between GISTs and other cancers by both site and histological type. These associations may carry important clinical implications for future cancer screening and treatment strategies.
Authors: Giuseppe Cavallaro; Ursula Basile; Andrea Polistena; Sandra Giustini; Rossella Arena; Alessandro Scorsi; Laura Zinnamosca; Claudio Letizia; Stefano Calvieri; Giorgio De Toma Journal: Am Surg Date: 2010-04 Impact factor: 0.688
Authors: Grace L Ma; James D Murphy; Maria E Martinez; Jason K Sicklick Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-10-02 Impact factor: 4.254
Authors: Jorge de la Torre; Sudeep Banerjee; Joel Baumgartner; Grace Y Lin; Adam M Burgoyne; Amanda Kirane; Jason Sicklick Journal: J Gastrointest Surg Date: 2018-08-21 Impact factor: 3.452
Authors: Shawn J Mendonca; Alejandro Sanchez; Kyle A Blum; Mazyar Ghanaat; Mahyar Y Kashan; Nicole Benfante; Paul Russo; Jonathan A Coleman; Aimee M Crago; A Ari Hakimi Journal: J Surg Oncol Date: 2018-06-07 Impact factor: 3.454
Authors: Taylor M Coe; Katherine E Fero; Paul T Fanta; Robert J Mallory; Chih-Min Tang; James D Murphy; Jason K Sicklick Journal: J Gastrointest Surg Date: 2016-03-29 Impact factor: 3.452
Authors: J A Fernández; V Olivares; A J Gómez-Ruiz; B Ferri; M D Frutos; T Soria; G Torres; P Parrilla Journal: Clin Transl Oncol Date: 2018-10-27 Impact factor: 3.405
Authors: Eleftherios A Makris; Ashwyn K Sharma; Erik N Bergstrom; Xiaojun Xu; Jorge de la Torre; Sudeep Banerjee; Vi Nguyen; Mojgan Hosseini; Adam Burgoyne; Olivier Harismendy; Ludmil B Alexandrov; Jason K Sicklick Journal: JCO Precis Oncol Date: 2021-03-19